Research progresses in neuroprotective effects of ischemic/hypoxia preconditioning

doi:10.3969/j.issn.1006-7795.2020.04.029

Abstract

Abstract: The brain has poor tolerance to ischemia and hypoxia, which could result in dysfunction and pathological changes of central nervous system. Both endogenous factors such as ischemic stroke and cancer and exogenous factors such as plateau exposure, aviation, and diving can lead to ischemia and hypoxia of the body or organs. Therefore, it is of great significance to develop strategies to improve cerebral hypoxic tolerance to prevent from ischemic and hypoxic diseases. Many studies have shown that exposure to moderate ischemia and hypoxia in a short period of time can significantly strengthen the body's tolerance to subsequent more severe hypoxia. This phenomenon is known as ischemia/hypoxia preconditioning. As a neuroprotective strategy, ischemia/hypoxia preconditioning has become one of the hotspots in biomedical research, and it has been applied in a variety of preclinical models such as ischemic stroke and neurodegenerative diseases. The protective mechanism of ischemia/hypoxia preconditioning is complex, which involves hypoxia signaling pathway activation, antioxidant stress, anti-inflammatory, anti-apoptosis, and so on. In this work, we reviewed the protective mechanisms and the research progresses of ischemia/hypoxia preconditioning to highlight its application potential in the treatment of neurological diseases.

Key words: hypoxia, ischemic, preconditioning, neuroprotection

CLC Number:

Q189

Wu Jian, Gu Yakun, Liu Jia. Research progresses in neuroprotective effects of ischemic/hypoxia preconditioning[J]. Journal of Capital Medical University, 2020, 41(4): 664-670.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.04.029

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I4/664

References 58

[1]	Murry C E, Jennings R B, Reimer K A. Preconditioning with ischemia:a delay of lethal cell injury in ischemic myocardium[J]. Circulation, 1986, 74(5):1124-1136.
[2]	Hausenloy D J and Yellon D M. Ischaemic conditioning and reperfusion injury[J]. Nat Rev Cardiol, 2016, 13(4):193-209.
[3]	McDonough A, Weinstein J R. The role of microglia in ischemic preconditioning[J]. Glia, 2020, 68(3):455-471.
[4]	Li C, Xu M, Wu Y, et al. Limb remote ischemic preconditioning attenuates lung injury after pulmonary resection under propofol-remifentanil anesthesia:a randomized controlled study[J]. Anesthesiology, 2014, 121(2):249-259.
[5]	Li S, Hafeez A, Noorulla F, et al. Preconditioning in neuroprotection:from hypoxia to ischemia[J]. Prog Neurobiol, 2017, 157:79-91.
[6]	Ekeloef S, Homilius M, Stilling M, et al. The effect of remote ischaemic preconditioning on myocardial injury in emergency hip fracture surgery (PIXIE trial):phase Ⅱ randomised clinical trial[J]. BMJ, 2019, 367:l6395.
[7]	Lee P, Chandel N S, Simon M C. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. (2020-05-14).. https://doi:10.1038/s41580-020-0227-y.
[8]	Zhu T, Zhan L, Liang D, et al. Hypoxia-inducible factor 1alpha mediates neuroprotection of hypoxic postconditioning against global cerebral ischemia[J]. J Neuropathol Exp Neurol, 2014, 73(10):975-986.
[9]	Apte R S, Chen D S, Ferrara N. VEGF in signaling and disease:beyond discovery and development[J]. Cell, 2019, 176(6):1248-1264.
[10]	Shao G, Gao C Y, Lu G W. Alterations of hypoxia-inducible factor-1 alpha in the hippocampus of mice acutely and repeatedly exposed to hypoxia[J]. Neurosignals, 2005, 14(5):255-261.
[11]	Veys K, Fan Z, Ghobrial M, et al. Role of the GLUT1 glucose transporter in postnatal CNS angiogenesis and blood-brain barrier integrity. Circ Res. (2020-05-14).. https://doi:10.1161/CIRCRESAHA.119.316463.
[12]	Joost H G, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators:nomenclature, sequence characteristics, and potential function of its novel members (review)[J]. Mol Membr Biol, 2001, 18(4):247-256.
[13]	Kuhrt D, Wojchowski D M. Emerging EPO and EPO receptor regulators and signal transducers[J]. Blood, 2015, 125(23):3536-3541.
[14]	Bickler P E, Buck L T. Hypoxia tolerance in reptiles, amphibians, and fishes:life with variable oxygen availability[J]. Annu Rev Physiol, 2007, 69:145-170.
[15]	Stenzel-Poore M P, Stevens S L, Xiong Z, et al. Effect of ischaemic preconditioning on genomic response to cerebral ischaemia:similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states[J]. Lancet, 2003, 362(9389):1028-1037.
[16]	Divald A, Kivity S, Wang P, et al. Myocardial ischemic preconditioning preserves postischemic function of the 26S proteasome through diminished oxidative damage to 19S regulatory particle subunits[J]. Circ Res, 2010, 106(12):1829-1838.
[17]	Bolanos J P, Almeida A, Moncada S. Glycolysis:a bioenergetic or a survival pathway?[J]. Trends Biochem Sci, 2010, 35(3):145-149.
[18]	Sies H and Jones D P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol.(2020-03-30).. https://doi:10.1038/s41580-020-0230-3.
[19]	Bell K F, Al-Mubarak B, Fowler J H, et al. Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning[J]. Proc Natl Acad Sci U S A, 2011, 108(1):E1-2; author reply E3-4.
[20]	Nadtochiy S M, Baker P R, Freeman B A, et al. Mitochondrial nitroalkene formation and mild uncoupling in ischaemic preconditioning:implications for cardioprotection[J]. Cardiovasc Res, 2009, 82(2):333-340.
[21]	Kannurpatti S S. Mitochondrial calcium homeostasis:implications for neurovascular and neurometabolic coupling[J]. J Cereb Blood Flow Metab, 2017, 37(2):381-395.
[22]	Sheng R, Liu X Q, Zhang L S, et al. Autophagy regulates endoplasmic reticulum stress in ischemic preconditioning[J]. Autophagy, 2012, 8(3):310-325.
[23]	Azad P, Ryu J, Haddad G G. Distinct role of Hsp70 in Drosophila hemocytes during severe hypoxia[J]. Free Radic Biol Med, 2011, 51(2):530-538.
[24]	Shi K, Tian D C, Li Z G, et al. Global brain inflammation in stroke[J]. Lancet Neurol, 2019, 18(11):1058-1066.
[25]	Gelderblom M, Leypoldt F, Steinbach K, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke[J]. Stroke, 2009, 40(5):1849-1857.
[26]	Cui G H, Wu J, Mou F F, et al. Exosomes derived from hypoxia-preconditioned mesenchymal stromal cells ameliorate cognitive decline by rescuing synaptic dysfunction and regulating inflammatory responses in APP/PS1 mice[J]. FASEB J, 2018, 32(2):654-668.
[27]	Sen E, Basu A, Willing L B, et al. Pre-conditioning induces the precocious differentiation of neonatal astrocytes to enhance their neuroprotective properties[J]. ASN Neuro, 2011, 3(3):e00062.
[28]	Song W M, Colonna M. The identity and function of microglia in neurodegeneration[J]. Nat Immunol, 2018, 19(10):1048-1058.
[29]	Tang Y, Le W. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases[J]. Mol Neurobiol, 2016, 53(2):1181-1194.
[30]	Wang J, Xing H, Wan L, et al. Treatment targets for M2 microglia polarization in ischemic stroke[J]. Biomed Pharmacother, 2018, 105:518-525.
[31]	Bock F J, Tait S W G. Mitochondria as multifaceted regulators of cell death[J]. Nat Rev Mol Cell Biol, 2020, 21(2):85-100.
[32]	Miranda C, Fagundes D J, Miranda E, et al. The role of ischemic preconditioning in the expression of apoptosis-related genes in a rat model of intestinal ischemia-reperfusion injury[J]. Acta Cir Bras, 2019, 34(5):e201900501.
[33]	Olloquequi J, Cornejo-Cordova E, Verdaguer E, et al. Excitotoxicity in the pathogenesis of neurological and psychiatric disorders:therapeutic implications[J]. J Psychopharmacol, 2018, 32(3):265-275.
[34]	Magi S, Piccirillo S, Amoroso S. The dual face of glutamate:from a neurotoxin to a potential survival factor-metabolic implications in health and disease[J]. Cell Mol Life Sci, 2019, 76(8):1473-1488.
[35]	Fullana N, Gasull-Camos J, Tarres-Gatius M, et al. Astrocyte control of glutamatergic activity:downstream effects on serotonergic function and emotional behavior[J]. Neuropharmacology, 2020, 166:107914.
[36]	Gong J, Gong S, Zhang M, et al. Cerebral ischemic preconditioning reduces glutamate excitotoxicity by up-regulating the uptake activity of GLT-1 in rats[J]. Amino Acids, 2014, 46(6):1537-1545.
[37]	Stavoe A K H, Holzbaur E L F. Autophagy in Neurons[J]. Annu Rev Cell Dev Biol, 2019, 35:477-500.
[38]	Park H K, Chu K, Jung K H, et al. Autophagy is involved in the ischemic preconditioning[J]. Neurosci Lett, 2009, 451(1):16-19.
[39]	Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice[J]. Nature, 2006, 441(7095):880-884.
[40]	Grotta J C. tPA for stroke:important progress in achieving faster treatment[J]. JAMA, 2014, 311(16):1615-1617.
[41]	Dirnagl U, Becker K, Meisel A. Preconditioning and tolerance against cerebral ischaemia:from experimental strategies to clinical use[J]. Lancet Neurol, 2009, 8(4):398-412.
[42]	Emberson J, Lees K R, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke:a meta-analysis of individual patient data from randomised trials[J]. Lancet, 2014, 384(9958):1929-1935.
[43]	Wang W W, Chen D Z, Zhao M, et al. Prior transient ischemic attacks may have a neuroprotective effect in patients with ischemic stroke[J]. Arch Med Sci, 2017, 13(5):1057-1061.
[44]	Vellimana A K, Milner E, Azad T D, et al. Endothelial nitric oxide synthase mediates endogenous protection against subarachnoid hemorrhage-induced cerebral vasospasm. Stroke, 2011, 42:776-782.
[45]	Chan M T, Boet R, Ng S C, et al. Effect of ischemic preconditioning on brain tissue gases and pH during temporary cerebral artery occlusion[J]. Acta Neurochir Suppl, 2005, 95:93-96.
[46]	Sales A H A, Barz M, Bette S, et al. Impact of ischemic preconditioning on surgical treatment of brain tumors:a single-center, randomized, double-blind, controlled trial[J]. BMC Med, 2017, 15(1):137.
[47]	Manukhina E B, Downey H F, Shi X, et al. Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease[J]. Exp Biol Med (Maywood), 2016, 241(12):1351-1363.
[48]	Zhang K, Zhao T, Huang X, et al. Notch1 mediates postnatal neurogenesis in hippocampus enhanced by intermittent hypoxia[J]. Neurobiol Dis, 2014, 64:66-78.
[49]	Wei L, Sun C, Lei M, et al. Activation of Wnt/beta-catenin pathway by exogenous Wnt1 protects SH-SY5Y cells against 6-hydroxydopamine toxicity[J]. J Mol Neurosci, 2013, 49(1):105-115.
[50]	Mazumdar J, O'Brien W T, Johnson R S, et al. O2 regulates stem cells through Wnt/beta-catenin signalling[J]. Nat Cell Biol, 2010, 12(10):1007-1013.
[51]	Vaughn C B, Jakimovski D, Kavak K S, et al. Epidemiology and treatment of multiple sclerosis in elderly populations[J]. Nat Rev Neurol, 2019, 15(6):329-342.
[52]	Faissner S, Plemel J R, Gold R, et al. Progressive multiple sclerosis:from pathophysiology to therapeutic strategies[J]. Nat Rev Drug Discov, 2019, 18(12):905-922.
[53]	Van Kaer L, Postoak J L, Wang C, et al. Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE[J]. Cell Mol Immunol, 2019, 16(6):531-539.
[54]	Esen N, Katyshev V, Serkin Z, et al. Endogenous adaptation to low oxygen modulates T-cell regulatory pathways in EAE[J]. J Neuroinflammation, 2016, 13:13.
[55]	Halder S K, Kant R, and Milner R. Hypoxic pre-conditioning suppresses experimental autoimmune encephalomyelitis by modifying multiple properties of blood vessels[J]. Acta Neuropathol Commun, 2018, 6(1):86.
[56]	Prosser-Loose E J, Hassan A, Mitchell G S, et al. Delayed Intervention with Intermittent Hypoxia and Task Training Improves Forelimb Function in a Rat Model of Cervical Spinal Injury[J]. J Neurotrauma, 2015, 32(18):1403-1412.
[57]	Wei L, Fraser J L, Lu Z Y, et al. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats[J]. Neurobiol Dis, 2012, 46(3):635-645.
[58]	Oh J S, Ha Y, An S S, et al. Hypoxia-preconditioned adipose tissue-derived mesenchymal stem cell increase the survival and gene expression of engineered neural stem cells in a spinal cord injury model[J]. Neurosci Lett, 2010, 472(3):215-219.